D F Ransohoff

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Proteomics research to discover markers: what can we learn from Netflix?
    David F Ransohoff
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Clin Chem 56:172-6. 2010
  2. doi request reprint Cultivating cohort studies for observational translational research
    David F Ransohoff
    UNC CH, Chapel Hill, NC 27599, USA
    Cancer Epidemiol Biomarkers Prev 22:481-4. 2013
  3. ncbi request reprint Colon cancer screening in 2005: status and challenges
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, North Carolina 27599 7080, USA
    Gastroenterology 128:1685-95. 2005
  4. pmc Sources of bias in specimens for research about molecular markers for cancer
    David F Ransohoff
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 28:698-704. 2010
  5. ncbi request reprint Rules of evidence for cancer molecular-marker discovery and validation
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
    Nat Rev Cancer 4:309-14. 2004
  6. ncbi request reprint Lessons from controversy: ovarian cancer screening and serum proteomics
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, Bioinformatics Bldg 4103, Chapel Hill, NC 27599 7080, USA
    J Natl Cancer Inst 97:315-9. 2005
  7. pmc Assessment of serum proteomics to detect large colon adenomas
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Cancer Epidemiol Biomarkers Prev 17:2188-93. 2008
  8. ncbi request reprint How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, 4103 Bioinformatics Building, Chapel Hill, NC 27599 7080, USA
    J Clin Epidemiol 60:1205-19. 2007
  9. ncbi request reprint Bias as a threat to the validity of cancer molecular-marker research
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
    Nat Rev Cancer 5:142-9. 2005
  10. pmc What is the role of iFOBT in screening for colorectal cancer?
    David F Ransohoff
    CB7080, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Gut 56:1343-4. 2007

Research Grants

  1. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
  2. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006

Detail Information

Publications50

  1. doi request reprint Proteomics research to discover markers: what can we learn from Netflix?
    David F Ransohoff
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Clin Chem 56:172-6. 2010
    ..What is the role of better mathematical or statistical analysis in improving the situation?..
  2. doi request reprint Cultivating cohort studies for observational translational research
    David F Ransohoff
    UNC CH, Chapel Hill, NC 27599, USA
    Cancer Epidemiol Biomarkers Prev 22:481-4. 2013
    ..What are the reasons, and can observational cohorts be cultivated to provide strong and reliable answers to those questions? Experimental..
  3. ncbi request reprint Colon cancer screening in 2005: status and challenges
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, North Carolina 27599 7080, USA
    Gastroenterology 128:1685-95. 2005
  4. pmc Sources of bias in specimens for research about molecular markers for cancer
    David F Ransohoff
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 28:698-704. 2010
    ..An appreciation of the separateness of these two processes-and placing investigators with appropriate expertise in charge of each-may increase the reliability of research about cancer biomarkers...
  5. ncbi request reprint Rules of evidence for cancer molecular-marker discovery and validation
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
    Nat Rev Cancer 4:309-14. 2004
  6. ncbi request reprint Lessons from controversy: ovarian cancer screening and serum proteomics
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, Bioinformatics Bldg 4103, Chapel Hill, NC 27599 7080, USA
    J Natl Cancer Inst 97:315-9. 2005
    ..To address such threats and to realize the potential of new -omics technology will require application of appropriate rules of evidence in the design, conduct, and interpretation of clinical research about molecular markers...
  7. pmc Assessment of serum proteomics to detect large colon adenomas
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Cancer Epidemiol Biomarkers Prev 17:2188-93. 2008
    ..They also highlight the importance of understanding sources of "noise" and "bias" in studies of proteomics assays...
  8. ncbi request reprint How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, CB 7080, 4103 Bioinformatics Building, Chapel Hill, NC 27599 7080, USA
    J Clin Epidemiol 60:1205-19. 2007
    ..The objective is to help improve the reliability and efficiency of development of molecular markers for cancer diagnosis...
  9. ncbi request reprint Bias as a threat to the validity of cancer molecular-marker research
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
    Nat Rev Cancer 5:142-9. 2005
    ....
  10. pmc What is the role of iFOBT in screening for colorectal cancer?
    David F Ransohoff
    CB7080, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Gut 56:1343-4. 2007
  11. ncbi request reprint Cancer. Developing molecular biomarkers for cancer
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Science 299:1679-80. 2003
  12. ncbi request reprint Promises and limitations of biomarkers
    David F Ransohoff
    University of North Carolina at Chapel Hill, 27599 7360, USA
    Recent Results Cancer Res 181:55-9. 2009
    ..This essay discusses chance and bias as threats to validity that can explain the huge disconnect between promise and product, along with approaches to address those threats...
  13. ncbi request reprint Lessons from the UK sigmoidoscopy screening trial
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Lancet 359:1266-7. 2002
  14. ncbi request reprint Screening colonoscopy in balance. Issues of implementation
    David F Ransohoff
    Department of Medicine, CB 7080, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Gastroenterol Clin North Am 31:1031-44, vii. 2002
    ..Noninvasive methods for colon cancer screening may reduce the need for colonoscopy in the future...
  15. pmc Recommendations for post-polypectomy surveillance in community practice
    David F Ransohoff
    Department of Medicine and Epidemiology, CB 7080, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7080, USA
    Dig Dis Sci 56:2623-30. 2011
    ..Decisions about surveillance interval are based in part on polyp size, histology, and number...
  16. ncbi request reprint Clinical practice. Screening for colorectal cancer
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
    N Engl J Med 346:40-4. 2002
  17. ncbi request reprint Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback
    David F Ransohoff
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Am J Med 113:663-7. 2002
    ..Interventions should be considered to temper possible overenthusiasm for screening and treatment...
  18. ncbi request reprint Challenges and opportunities in evaluating diagnostic tests
    David F Ransohoff
    University of North Carolina at Chapel Hill, CB 7080 724 Burnett Womack, Chapel Hill, NC 27599 7080, USA
    J Clin Epidemiol 55:1178-82. 2002
    ....
  19. ncbi request reprint Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population
    Thomas F Imperiale
    Department of Medicine, Indiana University, and the Regenstrief Institute, Indianapolis, IN 46202, USA
    N Engl J Med 351:2704-14. 2004
    ..We compared an approach that identifies abnormal DNA in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons 50 years of age or older...
  20. ncbi request reprint Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review
    Nicholas Shaheen
    Division of Digestive Diseases and Nutrition, Center for Esophageal Disease and Swallowing, CB 7080, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7080, USA
    JAMA 287:1972-81. 2002
    ..Some have recommended that patients with chronic reflux symptoms undergo upper endoscopy to assess for Barrett esophagus and to screen for cancer...
  21. ncbi request reprint Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications
    Nicholas Shaheen
    Division of Digestive Diseases and Nutrition, Center for Esophageal Disease and Swallowing, CB 7080, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7080, USA
    JAMA 287:1982-6. 2002
    ..Applying data reviewed in the companion article, we propose practical answers to common clinical situations regarding care of patients with reflux. We also present an algorithm for treatment of patients with chronic GERD symptoms...
  22. doi request reprint Understanding differences in the guidelines for colorectal cancer screening
    Thomas F Imperiale
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Gastroenterology 138:1642-1647.e1. 2010
    ..In this issue of Gastroenterology, the editors present 2 expert perspectives on the colorectal screening guidelines published in the May 2008 issue of the journal...
  23. ncbi request reprint Interpretations of 'appropriate' minority inclusion in clinical research
    Giselle Corbie-Smith
    Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Am J Med 116:249-52. 2004
    ..To expand scientific knowledge about the health of minority populations, investigators should be expected to state which goal they have selected and why that goal is appropriate as compared with other possible goals...
  24. ncbi request reprint Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities
    Giselle Corbie-Smith
    Department of Social Medicine, University of North Carolina at Chapel Hill, CB 7240, Chapel Hill, NC 27599, USA
    J Clin Epidemiol 56:416-20. 2003
    ..Although federal initiatives mandate inclusion of minority groups in research, that inclusion has not translated to reporting of results that might guide therapeutic decisions...
  25. doi request reprint Five-year risk of colorectal neoplasia after negative screening colonoscopy
    Thomas F Imperiale
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
    N Engl J Med 359:1218-24. 2008
    ..The appropriate interval for endoscopic rescreening after a negative colonoscopic examination is uncertain...
  26. doi request reprint Variation in polyp detection rates at screening colonoscopy
    Thomas F Imperiale
    Division of Gastroenterology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Gastrointest Endosc 69:1288-95. 2009
    ..Variation in polyp detection among endoscopists has been used to justify the need for establishing quality standards for colonoscopy performance...
  27. pmc International variation in screening mammography interpretations in community-based programs
    Joann G Elmore
    Department of Medicine, University of Washington, Seattle, USA
    J Natl Cancer Inst 95:1384-93. 2003
    ..To evaluate international variability in mammography interpretation, we analyzed published reports from community-based screening programs from around the world...
  28. ncbi request reprint Achieving quality in flexible sigmoidoscopy screening for colorectal cancer
    O S Ashley
    School of Public Health, University of North Carolina at Chapel Hill, USA
    Am J Med 111:643-53. 2001
    ..This review describes elements that characterize high-quality examinations and identifies resources for in-depth information on performing flexible sigmoidoscopy...
  29. ncbi request reprint CON: Immediate colonoscopy is not necessary in patients who have polyps smaller than 1 cm on computed tomographic colonography
    David F Ransohoff
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Am J Gastroenterol 100:1905-7; discussion 1907-8. 2005
  30. ncbi request reprint Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy
    Pauline A Mysliwiec
    National Cancer Institute, Bethesda, Maryland 20892 7344, USA
    Ann Intern Med 141:264-71. 2004
    ..Guidelines recommend surveillance after polypectomy at 3 to 5 years for a small adenoma, and follow-up is not advised for hyperplastic polyps. The intensity of physicians' surveillance is largely unstudied...
  31. doi request reprint Implications of new colorectal cancer screening technologies for primary care practice
    Ann G Zauber
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Med Care 46:S138-46. 2008
  32. ncbi request reprint Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer
    Thomas F Imperiale
    Indiana University School of Medicine, Indiana University, Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA
    Ann Intern Med 139:959-65. 2003
    ..Colonoscopic screening for colorectal cancer has been suggested because sigmoidoscopy misses nearly half of persons with advanced proximal neoplasia...
  33. ncbi request reprint Virtual colonoscopy--what it can do vs what it will do
    David F Ransohoff
    JAMA 291:1772-4. 2004
  34. ncbi request reprint Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry trade
    Isaac M Lipkus
    Duke University Medical Center, Durham, NC 27701, USA
    Prev Med 37:513-9. 2003
    ....
  35. ncbi request reprint Fecal DNA tests for colorectal cancer
    David F Ransohoff
    N Engl J Med 346:1912-3; author reply 1912-3. 2002
  36. ncbi request reprint Results of screening colonoscopy among persons 40 to 49 years of age
    Thomas F Imperiale
    Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, USA
    N Engl J Med 346:1781-5. 2002
    ..The prevalence of colorectal lesions in persons 40 to 49 years of age, as identified on colonoscopy, has not been determined...
  37. doi request reprint Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service
    Anna P Schenck
    The Carolinas Center for Medical Excellence, Cary, NC 27511 8598, USA
    Cancer Epidemiol Biomarkers Prev 17:799-804. 2008
    ..Medicare claims have been used to measure CRC testing but the validity of using claims to measure fecal occult blood tests (FOBT) has not been established...
  38. ncbi request reprint Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia
    Robert H Fletcher
    Cancer 109:1925-6; author reply 1926. 2007
  39. ncbi request reprint A national survey of primary care physicians' methods for screening for fecal occult blood
    Marion R Nadel
    Centers for Disease Control and Prevention and American Cancer Society, Atlanta, Georgia 30341 3717, ISA
    Ann Intern Med 142:86-94. 2005
    ..Although the test is simple, implementation requires adherence to specific techniques of testing and follow-up of abnormal results...
  40. ncbi request reprint Data sources for measuring colorectal endoscopy use among Medicare enrollees
    Anna P Schenck
    The Carolinas Center for Medical Excellence, 100 Regency Forest, Suite 200, Cary, NC 27511 8598, USA
    Cancer Epidemiol Biomarkers Prev 16:2118-27. 2007
    ..We compared ascertainment of sigmoidoscopy and colonoscopy between three data sources: self reports, Medicare claims, and medical records...
  41. ncbi request reprint Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics
    James E Allison
    Division of Research, Kaiser Permanente Northern California Region, 2000 Broadway, Oakland, CA 94612 2304, USA
    J Natl Cancer Inst 99:1462-70. 2007
    ..Thus, improving the sensitivity of FOBT should make colon cancer screening programs that use these tests more effective...
  42. ncbi request reprint Have we oversold colonoscopy?
    David F Ransohoff
    Gastroenterology 129:1815. 2005
  43. ncbi request reprint Reader response to colonoscopy versus sigmoidoscopy
    Steven M Woolf
    Fam Med 38:311-2; author reply 312-3. 2006
  44. ncbi request reprint Gene-expression signatures in breast cancer
    David F Ransohoff
    N Engl J Med 348:1715-7; author reply 1715-7. 2003
  45. ncbi request reprint Discovery-based research and fishing
    David F Ransohoff
    Gastroenterology 125:290. 2003
  46. ncbi request reprint Predicting risk for the appearance of melanoma
    Frank L Meyskens
    J Clin Oncol 24:3522-3. 2006
  47. ncbi request reprint Evaluating discovery-based research: when biologic reasoning cannot work
    David F Ransohoff
    Gastroenterology 127:1028. 2004
  48. doi request reprint The process to discover and develop biomarkers for cancer: a work in progress
    David F Ransohoff
    J Natl Cancer Inst 100:1419-20. 2008
  49. pmc Improving colorectal cancer screening in primary care practice: innovative strategies and future directions
    Carrie N Klabunde
    Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Boulevard, Bethesda, MD 20892 7344, USA
    J Gen Intern Med 22:1195-205. 2007
    ..Active engagement and support of practices are essential for the enormous potential of CRC screening to be realized...
  50. ncbi request reprint Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study
    H Gilbert Welch
    VA Outcomes Group, White River Junction VA Medical Center, 215 N Main St, VA Outcomes Group, 11B, White River Junction, VT 05009, USA
    Arch Intern Med 167:2289-95. 2007
    ....

Research Grants5

  1. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
    ..abstract_text> ..
  2. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..